New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:24 EDTITMNInterMune upgraded to Outperform from Market Perform at Leerink
Leerink upgraded InterMune to Outperform saying data at the American Thoracic Society presents a strong case that favors the use Esbriet over Boehringer-Ingelheim's nintedanib in idiopathic pulmonary fibrosis. The firm keeps a $41 price target for shares.
News For ITMN From The Last 14 Days
Check below for free stories on ITMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
11:19 EDTITMNInterMune July weekly volatility elevated
Subscribe for More Information
July 17, 2014
12:42 EDTITMNInterMune receives FDA Breakthrough Therapy Designation for pirfenidone
InterMune announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. FDA. This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Pirfenidone is an investigational treatment for adult patients with idiopathic pulmonary fibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use